MA49849A - Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique - Google Patents

Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique

Info

Publication number
MA49849A
MA49849A MA049849A MA49849A MA49849A MA 49849 A MA49849 A MA 49849A MA 049849 A MA049849 A MA 049849A MA 49849 A MA49849 A MA 49849A MA 49849 A MA49849 A MA 49849A
Authority
MA
Morocco
Prior art keywords
antibody
treatment
oncolytic virus
breast cancer
colorectal cancer
Prior art date
Application number
MA049849A
Other languages
English (en)
Inventor
Sumita Shankar Bhatta
Edward Namserk Cha
Jennifer Lorraine Gansert
Joseph Paul Woodard
Original Assignee
Amgen Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Genentech Inc filed Critical Amgen Inc
Publication of MA49849A publication Critical patent/MA49849A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
MA049849A 2017-08-07 2018-08-06 Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique MA49849A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762542046P 2017-08-07 2017-08-07

Publications (1)

Publication Number Publication Date
MA49849A true MA49849A (fr) 2020-06-17

Family

ID=63556436

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049849A MA49849A (fr) 2017-08-07 2018-08-06 Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique

Country Status (11)

Country Link
US (1) US20200254037A1 (fr)
EP (1) EP3664844A1 (fr)
JP (1) JP2020530003A (fr)
CN (1) CN111246883A (fr)
AR (1) AR112405A1 (fr)
AU (1) AU2018314227A1 (fr)
CA (1) CA3071599A1 (fr)
MA (1) MA49849A (fr)
MX (1) MX2020001451A (fr)
TW (1) TW201912173A (fr)
WO (1) WO2019032431A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
CA3131529A1 (fr) * 2019-03-05 2020-09-10 Amgen Inc. Utilisation de virus oncolytiques pour le traitement du cancer
CN114057877A (zh) * 2020-08-07 2022-02-18 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
EP4196574A2 (fr) * 2020-08-14 2023-06-21 Mayo Foundation for Medical Education and Research Matériels et méthodes pour l'ablation d'un tissu biologique

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
EP0184365B1 (fr) 1984-12-04 1993-08-04 Eli Lilly And Company Traitement de tumeurs chez les mammifères
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ235329A (en) 1989-09-15 1992-01-29 Res Triangle Inst 20(s or rs)-camptothecin derivatives and pharmaceutical compositions
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
CA2346866A1 (fr) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Therapie combinee avec antagoniste du polypeptide vasoactif intestinal
WO2000040734A1 (fr) 1998-12-31 2000-07-13 Arch Development Corporation Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques
WO2000054795A1 (fr) 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Therapie combinee consistant a administrer un agent chimiotherapeutique et un virus oncolytique pour tuer des cellules cancereuses chez un sujet
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
ATE508635T1 (de) 2001-03-27 2011-05-15 Catherex Inc Virusvektoren und ihre verwendung bei therapeutischen methoden
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
WO2013006795A2 (fr) 2011-07-07 2013-01-10 Humanitas International Foundation Compositions antivirales et leurs méthodes d'utilisation
EP3553086A1 (fr) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Protéines de liaison à un antigène se liant à pd-l1
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
CA2955084C (fr) * 2014-07-16 2023-08-29 Transgene Sa Association de virus oncolytiques ayant des modulateurs de points de controle immunitaires
EP4245376A3 (fr) 2014-10-14 2023-12-13 Novartis AG Molécules d'anticorps de pd-l1 et leurs utilisations
CA3011157A1 (fr) * 2016-01-11 2017-07-20 Turnstone Limited Partnership Polytherapie a base d'un virus oncolytique et d'un inhibiteur de point de controle
WO2018170133A1 (fr) * 2017-03-15 2018-09-20 Amgen Inc. Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer

Also Published As

Publication number Publication date
WO2019032431A1 (fr) 2019-02-14
AU2018314227A8 (en) 2020-10-08
CA3071599A1 (fr) 2019-02-14
TW201912173A (zh) 2019-04-01
CN111246883A (zh) 2020-06-05
AU2018314227A1 (en) 2020-02-06
EP3664844A1 (fr) 2020-06-17
AR112405A1 (es) 2019-10-23
MX2020001451A (es) 2020-08-06
US20200254037A1 (en) 2020-08-13
JP2020530003A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
MA49849A (fr) Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
CY1123259T1 (el) Αντισωματα anti-pvrig και μεθοδοι χρησης
HK1253250A1 (zh) 抗-ctla-4抗體及其使用方法
SG10201912560YA (en) Anti-ctla-4 antibodies and methods of use thereof
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
SG10201912878UA (en) Antibodies against signal-regulatory protein alpha and methods of use
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
CL2016002462A1 (es) Anticuerpos anti-ox40 y métodos de uso
MA43640A (fr) Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
CL2016002156A1 (es) Anticuerpo que une erbb-2 y erbb-3
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
TR201900160T4 (tr) Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler.
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
CR20180296A (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
DK3052525T3 (da) Anti-epcam-antistoffer og anvendelsesfremgangsmåder
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
DK3645826T3 (da) Seal apparatus and methods of use
EP3105314A4 (fr) Dosages combinés de l'antigène de l'hépatite et kits pour la détection d'infections actives dues au virus de l'hépatite
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
HK1257199A1 (zh) 用於檢測cd37的抗體和測定
EP3127918A4 (fr) Anticorps ehd2 et son application dans la préparation d'un réactif de détection immunohistochimique pour le cancer du sein
ES2966980T3 (es) Detección de antígenos de Trichinella